Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1039 - 1045
Section I - De la conception à la production
DOI https://doi.org/10.1051/medsci/200925121039
Publié en ligne 15 décembre 2009
  1. Sisson J, Shapiro B, Beierwaltes WH, et al. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 1983; 96 : 209–17.
  2. Suresh C, Srivastava L. Investigators review potential of antibodies in cancer detection and therapy. J Nucl Med 1987; 28 : 143–7.
  3. Buchegger F, Press OW, Delaloye AB, Ketterer N. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Oncologist 2008; 13 : 657–67.
  4. Bellet D, Dangles-Marie V. Anticorps humanisés en thérapeutique. Med Sci (Paris) 2005; 21 : 1054–62
  5. DeNardo GL, DeNardo SJ, Balhorn R. Systemic radiotherapy can cure lymphoma : a paradigm for other malignancies ? Cancer Biother Radiopharm 2008; 23 : 383–97.
  6. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993; 20 : 75–88.
  7. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 2008; 359 : 613–26.
  8. Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 2007; 14 : 632–8.
  9. Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008; 45 : 118–25.
  10. Chatal JF, Kraeber-Bodéré F, Barbet J. Consolidation radioimmunotherapy of follicular lymphoma : a step towards cure ? Eur J Nucl Med Mol Imaging 2008; 35 : 1236–9.
  11. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26 : 5156–64.
  12. Bodet-Milin C, Kraeber-Bodéré F, Dupas B, et al. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica 2008; 93 : 390–7.
  13. Ivanov A, Swann R, Illidge T. New insights into the mechanisms of action of radioimmunotherapy in lymphoma. J Pharm Pharmacol 2008; 60 : 987–98.
  14. Wheldon TE. The radiobiological basis of total body irradiation. Br J Radiol 1997; 70 : 1204–7.
  15. Sharkey RM, Karacay H, Chang CH, et al. Improved therapy of non-Hodgkin’s lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 2005; 19 : 1064–9.
  16. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001; 98 : 2535–43.
  17. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981; 41 : 4354–60.
  18. Sharkey RM, Pykett MJ, Siegel JA, et al. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987; 47 : 5672–7.
  19. Buchegger F, Vacca A, Carrel S, et al. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer 1988; 41 : 127–34.
  20. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005; 46 : S115–27.
  21. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006; 18 : 615–21.
  22. Brouwers AH, Mulders PF, de Mulder PH, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005; 23 : 6540–8.
  23. Buchegger F, Pfister C, Fournier K, et al. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab’)2 fragments. J Clin Invest 1989; 83 : 1449–56.
  24. Schlom J, Eggensperger D, Colcher D, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992; 52 : 1067–72.
  25. Nilsson FY, Tolmachev V. Affibody molecules : new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Dev 2007; 10 : 167–75.
  26. Muyldermans S. Single domain camel antibodies : current status. J Biotechnol 2001; 74 : 277–302.
  27. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24 : 823–34.
  28. Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy : a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24 : 1705–11.
  29. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002; 94 : 1373–81.
  30. Liersch T, Meller J, Bittrich M, et al. Update of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal liver metastases : comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007; 14 : 2577–90.
  31. Ychou M, Azria D, Menkarios C,et al.Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab’)2 after resection of liver metastases from colorectal cancer.Clin Cancer Res 2008; 14 : 3487–93.
  32. Milowsky MI, Nanus DM, Kostakoglu L,et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22 : 2522–31.
  33. Bander NH, Milowsky MI, Nanus DM,et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23 : 4591–601.
  34. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002; 29 : 821–30
  35. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment : the future is radiant. Bone Marrow Transplant 2005; 36 : 1021–6.
  36. Sievers EL, Appelbaum FR, Spielberger RT,et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy : a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93 : 3678–84.
  37. Supiot S, Faivre-Chauvet A, Couturier O,et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 2002; 94 : 1202–9.
  38. Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity.Cancer 2002; 94 : 1215–23
  39. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100 : 1233–9.
  40. Zalutsky MR, Reardon DA, Akabani G,et al. Clinical experience with alpha-particle emitting 211At : treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008; 49 : 30–8.
  41. Roboz GJ, Bennett JM, Coleman M, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res 2007; 31 : 1141–4.
  42. Saphire EO, Parren PW, Pantophlet R, et al. Crystal structure of a neutralizing human IGG against HIV-1 : a template for vaccine design. Science 2001; 293 : 1155–9
  43. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 1998, 39, 1172–8.
  44. Flux G, Bardies M, Monsieurs M, et al. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys 2006; 16 : 47–59.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.